Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.
Tourmaline Bio’s pacibekitug has shown positive topline results from its ongoing Phase II TRANQUILITY trial, which is evaluating quarterly and monthly subcutaneous dosing of the IL-6 inhibitor in patients with elevated high-sensitivity c-reactive protein (hs-CRP) and chronic kidney disease (CKD).
This is the first time that pacibekitug or any IL-6 inhibitor has been tested in a clinical study with quarterly...
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
